The purpose of this study is to evaluate the pharmacokinetics and safety of ASC16 after 3-single dose(50mg、100mg、200mg) or fixed continuous dose(200mg) in healthy volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
50mg, Tablet
200mg, Tablet
First Hospital of Zhejiang Province
Hangzhou, Zhejiang, China
Peak plasma concentration (Cmax)
Pharmacokinetics (blood draws, pre- and post-dose)
Time frame: 27 days
Area under the plasma concentration versus time curve (AUC)
Pharmacokinetics (blood draws, pre- and post-dose)
Time frame: 27 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.